← All trials
NCT03878524
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 14, 2019
- Primary completion
- Feb 27, 2021
- Completion date
- Feb 27, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 52
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- OHSU Knight Cancer InstituteLead sponsor
- Oregon Health and Science UniversityCollaborator
- OHSU Knight Cancer InstituteOverall official - principal investigator
- OHSU Knight Cancer InstituteReponsible party - principal investigator
- Prospect Creek FoundationCollaborator
Drugs studied
- afatinib
- olaparib
- sorafenib
- venetoclax
- enzalutamide
- fluorouracil
- imatinib
- trametinib
- idelalisib
- nivolumab
- pembrolizumab
- lenvatinib
- leucovorin
- palbociclib
- panobinostat
- ponatinib
- ipilimumab
- sunitinib
- carboplatin
- pertuzumab
- vemurafenib
- ruxolitinib
- celecoxib
- sirolimus
- bevacizumab
- abiraterone
- dasatinib
- everolimus
- bortezomib
- vorinostat
- cabazitaxel
- cabozantinib
- oxaliplatin
- erlotinib
- tretinoin
Indications studied
- Anemia
- Breast Neoplasms
- Hodgkin Disease
- Lymphoma
- Lymphoma, Non-Hodgkin
- Multiple Myeloma
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Neoplasms
- Pancreatic Neoplasms
- Leukemia, Lymphocytic, Chronic, B-Cell
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Chronic-Phase
- Leukemia, Myeloid, Acute
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
- Lymphoma, Primary Cutaneous Anaplastic Large Cell
- Primary Myelofibrosis
- Prostatic Neoplasms, Castration-Resistant
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.